A live dengue virus vaccine carrying a chimeric envelope glycoprotein elicits dual DENV2-DENV4 serotype-specific immunity
On behalf of the Microbiology Dept, I congratulate Dr. Sariol and his team, for their latest publication in Nature Communications on the first proof of concept of a bivalent dengue vaccine (against two serotypes DENV2 and 4). This is of high importance to Puerto Rico, as it could simplify the vaccine design and, in the…